Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature

Kivity, Shaye; Katz, Uriel; Daniel, Natalie; Nussinovitch, Udi; Papageorgiou, Neofytos; Shoenfeld, Yehuda

doi:10.1007/s12016-009-8155-9

Cited by 87 publications

(87 citation statements)

References 355 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La dosis de IgG se ajusta hasta 1000 mg/kg de acuerdo con el grado de hipogammaglobulinemia, la gravedad de las infecciones y el daño de los órganos afectados. (GRADE A1) 7,46,47,48,49,50,51 R La primera infusión intravenosa para reemplazo en un paciente con IDP que no haya sido tratado previamente debe ser administrada a una velocidad de 0.5 a 1 mg/kg por minuto. Después de 15 minutos se debe incrementar la velocidad de 1.5 a 2.5 mg/kg por minuto.…”

Section: Dosis De Inmunoglobulinaunclassified

“…Los niveles para hipogammaglobulinemia varían de acuerdo con la edad. (GRADE B2) 46,224,225,226,227,228,229,230,231,232 R No se recomienda el uso rutinario de IgIV en la prevención de las infecciones postrasplante. La administración rutinaria no redujo el riesgo de infección viral, bacteriana o micótica.…”

Section: Síndrome De Rassmussenunclassified

“…(GRADE B1) 284,285,286,287,288 R Se recomienda la administración de 2 g/kg de IgIV divididos en 5 días como tratamiento adyuvante en pacientes con enfermedades ampollosas autoinmunitarias graves resistentes al tratamiento inmunosupresor o que tengan contraindicación para el tratamiento inmunosupresor de primera línea con corticosteroides sistémicos. (GRADE B1) R El uso de IgIV en psoriasis debe individualizarse y puede considerarse 1 o 2 g/kg para el control de formas graves y resistentes a otros tratamientos o que cursan con artritis psoriásica (GRADE B1) 46,285 R La IgIV puede usarse en casos seleccionados de urticaria crónica grave y resistente a otros tratamientos. (GRADE B1) 46,285 Enfermedades neuropsiquiátricas R No se recomienda la IgIV en pacientes con autismo.…”

Section: Misceláneosunclassified

See 2 more Smart Citations

Guía colombiana de práctica clínica para el uso de inmonuglobulinas en el tratamiento de reemplazo e inmunomodulación

Olivares

Olmos²,

Álvarez

et al. 2017

RAM

View full text Add to dashboard Cite

Immunoglobulins are heterodimeric proteins composed of 2 heavy chains and 2 light chains. Human immunoglobulin G (IgG) is a plasma derivative and contains more than 95% of IgG. The composition of IgG subclasses is similar to that of normal human plasma. Immunoglobulin therapy was first introduced more than 50 years ago, and its use has been described in numerous diseases. In Colombia, the importance of this immunomodulatory resource prompted the need for clinical practice guidelines to be available for its use. For this reason, a multidisciplinary group of experts was brought together and distributed in working groups, by specialties, in order to develop an initial manuscript. Systematic literature searches were undertaken; identified evidences were evaluated and classified to support a preliminary draft that was discussed, analyzed and amended. Recommendations were issued on the use of intravenous immunoglobulin in pathologies that include primary and secondary immunodeficiencies, autoimmune diseases, neurological disorders, infections, transplants and miscellaneous conditions; grades were assigned to each one of them according to the GRADE system. The final result translated into recommendations that are put forth with the purpose to inform, guide and support on optimal use of this immunomodulatory resource.

show abstract

Section: Dosis De Inmunoglobulinaunclassified

Section: Síndrome De Rassmussenunclassified

Section: Misceláneosunclassified

See 1 more Smart Citation

Guía colombiana de práctica clínica para el uso de inmonuglobulinas en el tratamiento de reemplazo e inmunomodulación

Olivares

Olmos²,

Álvarez

et al. 2017

RAM

View full text Add to dashboard Cite

show abstract

“…This estimate should consider reimbursement policies in place and in particular the indications covered for IVIG in auto-immune disorders [11]. Many countries face an imbalance in the plasma products use, thereby generating excess products (e.g.…”

Section: Financial Aspectsmentioning

confidence: 99%

Plasma fractionation in Asia–Pacific: challenges and perspectives

Burnouf

2011

ISBT Science Series

View full text Add to dashboard Cite

Patients in every country should have access to quality blood products. National health authorities play a critical role in ensuring that patients' needs are met with safe and cost-effective products. Fractionated plasma products, as other blood products, are essential therapeutics used in the prevention, management, and treatment of life-threatening conditions resulting from trauma, metabolic congenital deficiencies, immunological disorders or infections. A few high development index (HDI) countries in the region have sufficient access to a broad portfolio of plasma products (coagulation factors, immunoglobulin, albumin) through domestic (e.g. Australia, Japan, Korea) or contract (e.g. Singapore, New Zealand) plasma fractionation programmes. China is gradually establishing a modern plasma fractionation industry. Other countries face plasma product shortages leading to inappropriate clinical use of plasma for transfusion and of non-virally inactivated cryoprecipitate, and ultimately to inappropriate treatment of patients.The volume of plasma fractionated in the region is too low to meet the needs. The volume (about 6 million l) represents 20% of the total volume fractionated worldwide for 60% of the world population. There is a rationale to encourage plasma contract fractionation programmes or operation of domestic facilities (when justified) to use local resources. However, many challenges are being faced as national plasma fractionation programmes require a mature blood collection infrastructure. Unfortunately, several LDI countries lack a mature national blood programme and a legislative framework on national policies and legislation on blood donations. They lack a safe blood donor base and a well-organized, nationally coordinated blood transfusion services; their blood collection system is scattered among different entities, resulting in non-uniform screening and testing procedures. Financial and human resources are lacking. Still, a few countries (e.g. Hong Kong, Malaysia, Singapore, Taiwan) have strengthened the national blood programmes, national blood policies have been implemented and the management of the blood transfusion service improved, allowing to implement contract plasma fractionation programme with established fractionators. Others are considering initiating (Indonesia and Malaysia) or enhancing (Thailand) domestic fractionation.Plasma fractionation programmes require good awareness and understanding by national regulatory authorities on quality criteria of plasma products. Local plasma product market and potential trends should be evaluated to determine plasma needs and the capacity to implement collection of plasma by apheresis from volunteer dedicated donors to supplement recovered plasma as a source material for fractionation. Appropriate choice of a contract fractionation partner should be made and contract terms discussed carefully. The fractionation technology and product portfolio should be evaluated to make sure that intended products can meet domestic needs (e.g. range, potency and fo...

show abstract

“…This opened a new era for the treatment of autoimmune conditions with intravenous immunoglobulin. Since then, intravenous immunoglobulin has become an important treatment option in an everincreasing number of autoimmune diseases (Arson et al, 2009;Kivity et al, 2010;Mimouni et al, 2011) and, more recently, for the treatment of tumor metastases (Damianovich et al, 2009). Immune dysregulation and loss of self-tolerance are the keystones of autoimmunity (Agmon-Levin et al, 2011).…”

Section: Mechanisms Of Action Of Intravenous Immunoglobulinmentioning

confidence: 99%